This evidence-based review examines whether mifepristone poses a meaningful environmental risk through wastewater discharge. Conventional treatment plants remove the vast majority of mifepristone via sorption to sludge, with biodegradation playing a limited role. FDA environmental assessments — even using conservative zero-removal assumptions — conclude no significant environmental impact. Real-world influent concentrations are extremely low due to limited usage volume, and trace effluent residuals are further diluted in receiving waters. However, rural homes on septic systems warrant special consideration, as septic treatment achieves lower and more variable pharmaceutical removal than municipal plants. The article includes six primary sources from FDA dockets, Swedish environmental classification databases, and peer-reviewed studies.
Countinute reading
